Thanks for your wisdom regarding the company's financial history. I will have to dig into those a bit more...and learn more about technical aspects of businesses in general.One point regarding the placebo effect: CFS is known to be treatment-resistant. In fact, in 2005 a meta-analysis of treatment trials for CFS found that patients' placebo responses were lower than expected relative to most medical conditions (see http://www.ncbi.nlm.nih.gov/pubmed/15784798?ordinalpos=8&ito...The meta-analysis likely drew from some good and some mediocre studies, but its findings are consistent with physicians' experience treating CFS, and with the fact that CFS is chronic.Most well-planned treatment studies inevitably are able to find some weak or moderate improvements with the drug(s) - you know the sort, they use all sorts of pre- and post-test measures and scales, document whatever changes happen to be statistically significant, and conclude that the drug helps manage the disease, without curing it, and that future study is needed. Ampligen is the only drug I'm aware of that has produced complete and sustained recoveries in CFS patients, followed by long-term remissions when the drug is withdrawn and improvements when it's resumed. Not to mention the fact that there is a strong theoretical basis for why it works, regarding Rnase L and the antiviral pathway being upregulated in patients with CFS.*Think about it for a minute.* There are currently no drugs formally approved to treat CFS. Although many off-label drugs can help fight fatigue, none of them really cure the condition. Ampligen, the only pending CFS drug for FDA approval I'm aware of, works by fixing a specific mechanism of the immune system that's off in CFS, but not in other conditions (at least, not in other non-viral diseases).
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M